Top 10 products by sales 2008 - 2014

2008

EvaluatePharma predicts this situation will change dramatically by 2014: as shown below, seven out of the top ten best-selling drugs will be biologic drugs. Moreover, biologics drugs are predicted to account for a 75% of the revenues, an almost 2-fold increase in the relative contributions of biologic drugs to the sector.

2014

The reason for this expected change is generic competition for small molecule drugs that will be off-patent by 2014, including current best-sellers Nexium®, Lipitor®, Plavix®, Advair® and Diovan®. The report also notes that "anti-cancer antibodies appear set to easily become the most valuable therapeutic class of drug." The report also notes that some traditional Big Pharma companies stand to benefit from their association (partnering) or acquisition of biotechnology companies, with Roche being a clear example as purveyors of three of the top ten predicted best-selling drugs in 2014 (Avastin®, Rituxan® and Herceptin®) representing about one third of the revenues from these drugs. Notably absent from the list are companies like Pfizer and GlaxoSmithKline that today have drugs in the best-selling top ten. Accordingly, EvaluatePharma suggests that it may behoove such companies to pursue small and mid-sized biotech companies, particularly now during the economic downtrend that has reduced the valuations of these biotech companies.

Ver